PolyPid Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Approximately 3 2 0 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX 100 for the Prevention of Abdominal Colorectal Surgical Site Infections U nblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up , Which is Expected in F ourth